MDXG
MiMedx Group, Inc.
Biotechnology · Healthcare · United States
3.97
close · 2026-10-29
value
57
cheaper than peers57
quality
67
stronger fundamentals67
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.62× | 92 |
| price to book | 2.29× | 66 |
| EV to EBITDA | 22.04× | 45 |
| forward P/E | 37.81× | 20 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 2.9% | 82 |
| operating margin | -28.7% | 69 |
| debt to equity | 8.0% | 66 |
| revenue growth | -34.7% | 24 |
4 of 4 measures available
Facts
| market cap | $579M |
| free cash flow | $41.4M |
| employees | 808 |
| first trade | 2008-02-12 |
| next earnings | 2026-10-28 |
| fundamentals updated | 2026-10-28 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.32 | 0.28 | 0.37 | -0.33 |
| free cash flow | $73.0M | $64.5M | $24.8M | -$19.4M |
| net income | $48.6M | $42.4M | $58.2M | -$30.2M |
| revenue | $418.6M | $348.9M | $321.5M | $267.8M |
| unusual items | $0 | -$446,000 | $0 | $0 |